Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2015, Vol. 42 Issue (6): 730-735    DOI: 10.12891/ceog2010.2015
Original Research Previous articles | Next articles
Non-association of MMP-9 -1562C/T polymorphism with preeclampsia risk: evidence from a meta-analysis
C. M. Wang1, *(), S. L. Zhang2
1Department of Gynecology and Obstetrics, The Second Affiliated Hospital of the Southeast University, Nanjing
2Department of General Surgery, Zhongda Hospital, Medical College of Southeast University, Nanjing (China)
Download:  PDF(305KB)  ( 6 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Individual genetic association studies examining the relationship between the MMP-9 -1562C/T polymorphism (rs3918242) and preeclampsia risk have yielded inconsistent results. Objective: This study aims to evaluate the association between the MMP-9 - 1562C/T polymorphism and preeclampsia risk using meta-analysis. Materials and Methods: Relevant studies were identified by searching PubMed database. Data were extracted and statistical analysis was performed using STATA 12.0 software. A total of six publications involving 871 cases and 845 controls were included in this meta-analysis. Results: Combined analysis revealed no association between the MMP-9 -1562C/T polymorphism and preeclampsia risk (allelic model: OR = 1.10, 95% CI 0.86 - 1.41, Pheterogeneity= 0.07; recessive model: OR = 0.38, 95% CI 0.14-1.01, Pheterogeneity= 0.64; dominant model: OR = 1.09, 95% CI 0.70 - 1.69, Pheterogeneity = 0.01; homozygous model: OR = 0.41, 95% CI 0.15 - 1.09, Pheterogeneity = 0.67; heterozygous model: OR = 1.36, 95% CI 0.80 - 2.29, Pheterogeneity = 0.01). Similarly, subgroup analysis by ethnicity showed that MMP-9 -1562C/T polymorphism was not associated with preeclampsia risk in Brazilian (allelic model: OR = 1.37, 95% CI 0.92 - 2.05, Pheterogeneity= 0.61; recessive model: OR = 0.80, 95% CI 0.18 - 3.57, Pheterogeneity= 0.58; dominant model: OR = 1.12, 95%CI 0.60-2.10, Pheterogeneity= 0.03; homozygous model: OR = 0.87, 95%CI 0.19-3.94, Pheterogeneity = 0.62; heterozygous model: OR = 1.55, 95% CI 0.99 - 1.75, Pheterogeneity = 0.32). Conclusion: This meta-analysis indicated that MMP-9 -1562C/T polymorphism was not associated with preeclampsia risk. However, large welldesigned, multi-center epidemiological studies should be carried out in these and other ethnic populations to confirm our findings.
Key words:  MMP-9      Polymorphism      Preeclampsia      Meta-analysis     
Published:  10 December 2015     
*Corresponding Author(s):  C. M. WANG     E-mail:  wcmwcmlove@163.com

Cite this article: 

C. M. Wang, S. L. Zhang. Non-association of MMP-9 -1562C/T polymorphism with preeclampsia risk: evidence from a meta-analysis. Clinical and Experimental Obstetrics & Gynecology, 2015, 42(6): 730-735.

URL: 

https://ceog.imrpress.com/EN/10.12891/ceog2010.2015     OR     https://ceog.imrpress.com/EN/Y2015/V42/I6/730

[1] Zhu Chen, Hui Huang, Jingcen Hu, Shuyu Wang, Liang Xia. Circulating neutrophil gelatinase-associated lipocalin and gestational diabetes mellitus: a meta-analysis[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1206-1214.
[2] Luca Roncati, Greta Gianotti, Elisa Ambrogi, Giovanna Attolini. COVID-19 in pregnancy[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 778-780.
[3] Zhongying Huang, Zhun Xiao, Qianhong Ma, Yu Bai, Feilang Li. Efficacy of tamoxifen for infertile women with thin endometrium undergoing frozen embryo transfer: a meta-analysis[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 806-811.
[4] Silvia Amodeo, Giulia Bonavina, Anna Seidenari, Paolo Ivo Cavoretto, Antonio Farina. Real-world implementation and adaptation to local settings of first trimester preeclampsia screening in Italy: a systematic review[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 812-819.
[5] Shingo Tanaka, Maki Goto, Saya Watanabe, Sachino Kira, Sotaro Hayashi, Shigeki Fujimoto, Miho Oda, Lifa Lee, Yoko To, Satoshi Nishiyama, Fuyuki Eguchi, Hiroshi Tsujioka. Posterior reversible encephalopathy syndrome with reversible cerebral vasoconstriction syndrome in a normal primigravida woman at the 35-week gestational stage: a case report[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 982-986.
[6] Lejla Kamerić, Anis Cerovac, Mirzeta Rizvanović, Alen Kamerić, Mahira Jahić, Dubravko Habek. Frequency of cesarean section in pregnant women with risk factors for preeclampsia: prospective cohort study[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(3): 561-566.
[7] Elisa Casella, Carla Ettore, Ferdinando Antonio Gulino, Elisa Pappalardo, Filippo Rapisarda, Stella Capriglione, Giuseppe Ettore. Two successful pregnancies after a simultaneous kidney and pancreas transplantation for type 1 diabetes mellitus-complicated nephropathy[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(3): 697-699.
[8] Yi Zhou, Ran Wang, Shi-Xian Chen, Li-Sheng Wu, Jun-Qing Zhu. Matrix metalloproteinase 9 gene promoter region -1562 C/T single nucleotide polymorphism increases the susceptibility to hypertensive disorders of pregnancy: a meta-analysis[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(2): 245-252.
[9] Shi-Fu Hu, Ying-Ying Wang, Yan-Qing Wu, Qiong Yu. Timing of prophylactic antibiotic use during elective caesarean section: a meta-analysis of randomised controlled trials[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(1): 31-36.
[10] Jing Wang, Min Zhou, Li Zhang, Long-Xin Zhang. Effective doses 50% and 95% of subarachnoid injection of sufentanil with ropivacaine in lumbar anesthesia for cesarean section in severe preeclampsia[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(1): 105-109.
[11] R. Mihăilă. Coagulation challenges in pregnancy: from thrombophilia involvement and management to the utility of thrombin generation monitoring[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(6): 814-820.
[12] Y. Sun, X. Chen, X. Yuan, L. Xu, Y.C. Jin, T.H. Ji, X.L. Wang, H.H. Dai, W.J. Cheng. Levonorgestrel intrauterine system versus oral progestin for preventing the recurrence of endometrial polyps after hysteroscopic resection: A meta-analysis of 19 randomized controlled trials[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(6): 821-828.
[13] J. Dun, X. Wang, J. Yang, J. Xu. Clinical practice guidelines on polycystic ovary syndrome: a systematic review and comparative meta-analysis[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 465-471.
[14] J. Wang, S.W. Chen, X.Y. Qin, X.Z. Zheng, P. Wang, X.Y. Cai. Clinical application of short tandem repeat polymorphism analysis in the differential diagnosis of early hydatidiform mole and hydropic abortion[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 490-495.
[15] H.M. Kim, Y.S. Choo, W.J. Seong. Serum NT-proBNP levels as a marker for cardiopulmonary function in preeclampsia[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 511-515.
No Suggested Reading articles found!